Literature DB >> 22439069

Current strategy for detection and diagnosis of hyperglycemic disorders in pregnancy.

Angelo Santamaria1, Pietro Cignini, Angelica Trapanese, Silvia Bonalumi.   

Abstract

Gestational diabetes mellitus (GDM) is a metabolic alteration frequently found in pregnant women. In women with GDM, failure of pancreatic beta-cells to adapt the production of insulin at the increased metabolic demand in pregnancy, results in a inadequate insulin response, with consequent hyperglycemia. The criteria currently used for the diagnosis of GDM are too restrictive as some author suggested that different degrees of hyperglycemia, even though not diagnostic for diabetes, increase the risks of adverse perinatal outcomes (large for gestational age (LGA), higher rate of cesarean section, neonatal hypo-glycemia, respiratory distress, perinatal mortality). The objective of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study was to clarify the associations of levels of maternal glucose, lower than those diagnostic of diabetes, with perinatal outcome, defining a new overall strategy recommended for detection and diagnosis of hyperglycemic disorders in pregnancy.

Entities:  

Keywords:  HAPO study; gestational diabetes mellitus (GDM); hyperglycemic disorders; pregnancy.

Year:  2011        PMID: 22439069      PMCID: PMC3279146     

Source DB:  PubMed          Journal:  J Prenat Med        ISSN: 1971-3282


  10 in total

1.  Proposal for the reconsideration of the definition of gestational diabetes.

Authors:  Yasue Omori; Lois Jovanovic
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

2.  Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee.

Authors:  B E Metzger; D R Coustan
Journal:  Diabetes Care       Date:  1998-08       Impact factor: 19.112

3.  Reflections on gestational diabetes mellitus.

Authors:  R J Jarrett
Journal:  Lancet       Date:  1981-11-28       Impact factor: 79.321

4.  Clinical impact of mild carbohydrate intolerance in pregnancy: a study of 2904 nondiabetic Danish women with risk factors for gestational diabetes mellitus.

Authors:  D M Jensen; P Damm; B Sørensen; L Mølsted-Pedersen; J G Westergaard; J Klebe; H Beck-Nielsen
Journal:  Am J Obstet Gynecol       Date:  2001-08       Impact factor: 8.661

5.  Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia.

Authors:  A Ferrara; N S Weiss; M M Hedderson; C P Quesenberry; J V Selby; I J Ergas; T Peng; G J Escobar; D J Pettitt; D A Sacks
Journal:  Diabetologia       Date:  2006-11-14       Impact factor: 10.122

6.  Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy.

Authors:  U M Schaefer; G Songster; A Xiang; K Berkowitz; T A Buchanan; S L Kjos
Journal:  Am J Obstet Gynecol       Date:  1997-11       Impact factor: 8.661

7.  Hyperglycemia and adverse pregnancy outcomes.

Authors:  Boyd E Metzger; Lynn P Lowe; Alan R Dyer; Elisabeth R Trimble; Udom Chaovarindr; Donald R Coustan; David R Hadden; David R McCance; Moshe Hod; Harold David McIntyre; Jeremy J N Oats; Bengt Persson; Michael S Rogers; David A Sacks
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

8.  Macrosomia--maternal characteristics and infant complications.

Authors:  W N Spellacy; S Miller; A Winegar; P Q Peterson
Journal:  Obstet Gynecol       Date:  1985-08       Impact factor: 7.661

9.  Screening tests for gestational diabetes in Japan in the 1st and 2nd trimester of pregnancy.

Authors:  Yuka Maegawa; Takashi Sugiyama; Hideto Kusaka; Masaru Mitao; Nagayasu Toyoda
Journal:  Diabetes Res Clin Pract       Date:  2003-10       Impact factor: 5.602

10.  Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics.

Authors: 
Journal:  Diabetes       Date:  2008-11-14       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.